Press Releases

and/or
572 News Releases found
Michelle S. Bradbury
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.
Harold Varmus
Memorial Sloan Kettering Cancer Center has announced the gift of a membership interest in Geoffrey Beene, LLC, the company that controls the business and fashion empire created by legendary designer Geoffrey Beene.
New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.
Maureen Killackey, MD
Memorial Sloan Kettering Cancer Center and Summit Medical Group together announce a new collaborative relationship for the care of people with cancer.
James Blake
American tennis player and World No. 8 ranked James Blake will formally announce today the launch of the Thomas Blake, Sr., Memorial Research Fund, which he established to support cancer research at Memorial Sloan Kettering Cancer Center.
Robert Motzer, MD
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.
A study led by researchers at Memorial Sloan Kettering Cancer Center has uncovered how breast tumors use a particular type of molecule to promote metastasis - the spread of cancer cells.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Dr. Kenneth Offit, MD, MPH
The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center (MSKCC).
Chau Dang, MD
Media Advisory
A new pilot study by investigators at Memorial Sloan Kettering Cancer Center found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.